Rating on Surmodics (NASDAQ:SRDX) is Set to Buy. Its Keeps by Needham with $55 Target.

May 17, 2018 - By Benjamin Allen

Surmodics, Inc. (NASDAQ:SRDX) Corporate Logo

Big Money Sentiment decreased to 0.69 in 2017 Q4. It has change of 0.25, from 2017Q3’s 0.94. The ratio dropped due to Surmodics, Inc. positioning: 11 sold and 44 reduced. 12 funds bought stakes and 26 increased stakes. Investors holded 11.18 million in 2017Q3 but now own 11.07 million shares or 0.98% less.

Moreover, Strs Ohio has 0% invested in Surmodics, Inc. (NASDAQ:SRDX) for 23,800 shs. Citadel Advsr Ltd Liability Co holds 0% or 14,528 shs in its capital. Moreover, Meristem Ltd Liability Partnership has 0.08% invested in Surmodics, Inc. (NASDAQ:SRDX) for 8,196 shs. 29,502 were reported by Prudential Fincl. Alliancebernstein L P owns 28,921 shs for 0% of their capital. Wells Fargo Mn has invested 0% of its capital in Surmodics, Inc. (NASDAQ:SRDX). Invesco Ltd has 44,719 shs for 0% of their capital. The New York-based Gabelli Funds Ltd Liability Co has invested 0.02% in Surmodics, Inc. (NASDAQ:SRDX). Acadian Asset Ltd Llc reported 0.02% in Surmodics, Inc. (NASDAQ:SRDX). Vanguard Grp holds 0% of its capital in Surmodics, Inc. (NASDAQ:SRDX) for 729,688 shs. Price T Rowe Md accumulated 0% or 8,686 shs. 15 are held by Parkside Fin Bancorporation Tru. 9,390 are owned by Us Financial Bank De. Gemmer Asset Mngmt Limited Liability Co holds 136 shs or 0% of its capital. Gamco Et Al owns 100,448 shs.

Surmodics, Inc. had 2 selling transactions and 0 insider purchases since December 11, 2017. This’s net activity of $63,711.

Reiterated Surmodics (NASDAQ:SRDX) Rating.

On Wednesday, 16 May Needham have a $55 PT on Surmodics (NASDAQ:SRDX). A upside potential of 11.79 % have this PT. The $652.29M market cap company have Buy stock rating released in a report.

Surmodics, Inc. (NASDAQ:SRDX) Ratings Coverage

Total analysts of 2 have positions in Surmodics (NASDAQ:SRDX) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. The firm has $5500 highest while $42 is the lowest target. The average target $55 is 11.79% above the last ($49.2) price. Since February 28, 2018 according to StockzIntelligence Inc Surmodics has 4 analyst reports. On Wednesday, February 28 the firm earned “Outperform” rating by Barrington Research. On Wednesday, May 2 the rating was maintained by Needham with “Buy”. In Wednesday, May 16 report Needham maintained it with “Buy” rating and $5500 target.

Ticker’s shares touched $49.2 during the last trading session after 5.24% change.Surmodics, Inc. is uptrending after having risen 61.37% since May 17, 2017. SRDX has 114,997 volume or 113.73% up from normal. The stock outperformed the S&P500 by 49.82%.

On August, 2 WallStreet anticipated Surmodics, Inc. (NASDAQ:SRDX)’s earnings report, Zacks reports. Analysts predict $-0.08 EPS, which is $0.17 down or 188.89 % from 2017’s $0.09 EPS. After $0.07 EPS was reported last quarter, analysts now see negative EPS growth of -214.29 % for Surmodics, Inc..

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland.The company has $652.29 million market cap. It operates through two divisions, Medical Device and In Vitro Diagnostics.The P/E ratio is 24600. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

For more Surmodics, Inc. (NASDAQ:SRDX) news released briefly go to: Seekingalpha.com, Globenewswire.com, Bizjournals.com, Benzinga.com or Benzinga.com. The titles are as follows: “FDA clears Surmodic’ low-profile catheter” released on April 23, 2018, “Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA …” on May 01, 2018, “SurModics CFO LaFrence leaves for pharma company” with a publish date: May 16, 2018, “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” and the last “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” with publication date: May 15, 2018.

Surmodics, Inc. (NASDAQ:SRDX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: